The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation

Doggrell, Sheila A. (2003) The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation. Expert Opinion on Investigational Drugs, 12 5: 805-823. doi:10.1517/13543784.12.5.805


Author Doggrell, Sheila A.
Title The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation
Journal name Expert Opinion on Investigational Drugs   Check publisher's open access policy
ISSN 1354-3784
1744-7658
Publication date 2003-05
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1517/13543784.12.5.805
Open Access Status Not yet assessed
Volume 12
Issue 5
Start page 805
End page 823
Total pages 19
Place of publication Abingdon, Oxfordshire, United Kingdom
Publisher Taylor & Francis
Language eng
Formatted abstract
The main peripheral sources of 5-hydroxytryptamine (5-HT) are as a neurotransmitter and local hormone in the gastrointestinal tract, and stored in circulating platelets and pulmonary neuroepithelial bodies. 5-HT has been shown to have many possible physiological and pathophysiological roles on the cardiovascular and renal systems. Thus, 5-HT may contribute to valvular heart disease, coronary artery disease, pulmonary hypertension, pulmonary embolism, pre-eclampsia, peripheral vascular disease and diabetic nephropathy. Consequently, modulators of the 5-HT system have diverse clinical potential. For instance, selective 5-HT subtype 3 receptor (5-HT3) antagonists may have potential in the treatment of the pain associated with myocardial infarction. MCI-9042 (sarpogrelate) or other 5-HT2A antagonists may have clinical potential for the treatment of vasospastic angina, ischaemic heart disease, reperfusion injury and hindlimb ischaemia. Several modulators of 5-HT (5-HT transporter inhibitors, 5-HT1B and 2B antagonists) may have potential alone or in combination in the treatment of pulmonary hypertension. In hypertension, agonists at the 5-HT7 and antagonists at the 5-HT2B may reduce blood pressure, and in diabetes, sarpogrelate may protect against nephropathy.
Keyword 5-HT
5-HT receptor agonists
5-HT receptor antagonists
Pathophysiology
Peripheral cardiovascular
Renal
Sarpogrelate
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collection: School of Biomedical Sciences Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 34 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 36 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 28 Jun 2016, 07:35:57 EST by System User on behalf of Learning and Research Services (UQ Library)